What Medications Work Like Ozempic? A Guide to GLP-1 Receptor Agonists

Ozempic has become shorthand for an entire class of drugs — the way “Kleenex” became synonymous with tissues. But semaglutide, the active compound in Ozempic and Wegovy, is just one member of a larger pharmacological family that works through the same fundamental mechanism: activating glucagon-like peptide-1 receptors to suppress appetite, slow gastric emptying, and improve blood sugar regulation. If you’re exploring this space — whether because Ozempic is unavailable, too expensive, or simply not the right fit — understanding which medications share its mechanism, and how they compare, is essential before making any decision with your doctor.

The clinical data on semaglutide is genuinely impressive. A 2022 systematic review and meta-analysis covering more than 3,600 individuals with obesity but without diabetes found that subcutaneous semaglutide produced an average weight reduction of 11.85% from baseline compared to placebo — a clinically meaningful result that puts it well beyond what most traditional interventions achieve. But semaglutide didn’t arrive in a vacuum. It’s the most potent member of a GLP-1 receptor agonist (GLP-1RA) class that includes several other approved medications, each with its own dosing schedule, efficacy profile, and side effect burden.

The GLP-1 Receptor Agonist Family: Who’s in the Class

The most direct comparison to Ozempic is liraglutide, sold under the brand names Victoza (diabetes dosing) and Saxenda (obesity dosing). Like semaglutide, liraglutide is a GLP-1 analogue injected subcutaneously — but it requires daily administration rather than once-weekly dosing, which matters enormously for adherence. The STEP 8 trial published in JAMA put these two medications head-to-head in a rigorous 68-week randomized clinical trial, and the results were not close. Once-weekly semaglutide at 2.4 mg produced a mean weight loss of 15.8%, compared to just 6.4% with daily liraglutide at 3.0 mg — a difference of more than 9 percentage points. Participants taking semaglutide were also significantly more likely to achieve 10%, 15%, and 20% weight loss thresholds, and fewer discontinued treatment (13.5% vs 27.6%). The side effect profiles were broadly similar, with gastrointestinal events reported in roughly 84% of semaglutide users and 83% of liraglutide users.

Liraglutide isn’t obsolete — it’s FDA-approved, widely prescribed, and has a longer real-world track record — but the efficacy gap is substantial enough that most clinicians now view semaglutide as the preferred GLP-1RA when cost and access aren’t prohibitive. That said, liraglutide remains a legitimate option for patients who can’t tolerate once-weekly injections or who respond well at lower efficacy thresholds.

Then there’s tirzepatide, sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for obesity). Tirzepatide operates through a dual mechanism — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, which is why it’s technically classified as a “dual incretin agonist” rather than a pure GLP-1RA. In clinical trials, tirzepatide has produced weight loss numbers that exceed even semaglutide, with some patients losing more than 20% of body weight. A 2025 real-world evidence review confirmed that among currently approved weight-loss therapies in this class — liraglutide, semaglutide, and tirzepatide — outcomes in clinical practice tend to track with adherence, and tirzepatide and semaglutide are consistently the strongest performers. The review also noted discontinuation rates of 20% to 50% within the first year across all agents, driven primarily by gastrointestinal side effects and cost — a practical reality that any man considering these medications needs to factor in from the start.

Exenatide (Byetta, twice daily; Bydureon, once weekly) was one of the earliest GLP-1RAs approved and deserves mention for historical context, though it has largely been displaced by newer agents with superior efficacy and more convenient dosing. Dulaglutide (Trulicity) is another once-weekly injectable GLP-1RA with solid cardiovascular outcome data, though its weight loss effect is more modest than semaglutide. Albiglutide (Tanzeum) was withdrawn from the US market in 2018 for commercial reasons rather than safety concerns. None of these older agents match the weight loss efficacy of semaglutide or tirzepatide.

Beyond Weight Loss: What These Medications Are Also Doing

One of the more surprising developments in GLP-1 research over the past few years is the accumulating evidence that these drugs affect behavior far beyond the plate. The STEP 3 trial demonstrated that when semaglutide was combined with intensive behavioral therapy and an initial low-calorie diet, participants achieved a mean weight loss of 16% at 68 weeks — compared to 5.7% with behavioral therapy and placebo alone — suggesting that the pharmacological effect stacks meaningfully on top of lifestyle intervention rather than replacing it. This is an important message for men who are already doing the work in the gym and kitchen: GLP-1RAs appear to amplify effort, not substitute for it.

Perhaps more striking is the emerging evidence around addiction and compulsive behavior. A 2025 randomized clinical trial published in JAMA Psychiatry tested once-weekly semaglutide in adults with alcohol use disorder and found that even low-dose semaglutide significantly reduced alcohol craving, drinks per drinking day, and heavy drinking episodes relative to placebo — with medium to large effect sizes. The same study found that semaglutide predicted greater reductions in cigarettes per day among current smokers. These findings suggest that GLP-1 receptors are involved in reward circuitry more broadly, and researchers are now actively investigating applications for nicotine dependence, food addiction, and other compulsive behaviors. The clinical implications are still early-stage, but for men dealing with more than just excess weight, this science is worth watching closely.

The mechanism behind these effects likely involves GLP-1 receptors in the brain’s mesolimbic dopamine system — the same reward circuitry implicated in substance use, compulsive eating, and craving-driven behavior. When GLP-1RAs activate receptors in areas like the nucleus accumbens and ventral tegmental area, they appear to dampen the reward signal associated with alcohol, food, and potentially other reinforcing substances. This is fundamentally different from how older anti-obesity drugs worked, which is part of why the GLP-1 class feels qualitatively different to many patients.

Choosing the Right Option — and What to Expect in the Real World

If you’re working with a physician to explore this class of medications, the decision tree generally starts with what’s covered by your insurance and what’s available through your pharmacy. Semaglutide and tirzepatide are the most efficacious options currently approved in the United States, but both carry significant out-of-pocket costs without insurance coverage. Liraglutide is more established in the system and may be covered more readily in some plans, though its efficacy disadvantage relative to semaglutide is real and documented.

Real-world outcomes are also consistently lower than trial outcomes, and the 2025 narrative review is candid about why: patients in the real world use lower doses, are less adherent, and discontinue more frequently than participants in tightly controlled trials. The men who achieve trial-level results in clinical practice are, by and large, the ones who treat their GLP-1RA as one component of a comprehensive approach — not a substitute for nutrition, resistance training, and sleep. That framework applies regardless of which specific agent you’re using.

Side effects across the class are broadly similar: nausea, vomiting, diarrhea, and constipation are the most common, typically peaking during dose escalation and attenuating over time. Slower titration schedules reduce the severity of these effects considerably, which is one practical lever your physician can adjust if tolerability becomes an issue. The real-world data is reassuring on serious adverse events — no clear signal for pancreatitis, pancreatic cancer, or thyroid malignancy at the population level, though monitoring remains appropriate.

The Takeaway

Ozempic didn’t invent GLP-1 receptor activation — it just became the most visible example of what this class can do. Semaglutide remains the most rigorously studied and highest-efficacy pure GLP-1RA for weight management, but tirzepatide has emerged as a legitimate challenger with even greater weight loss in trials. Liraglutide is a viable alternative for men who need a different dosing structure or have insurance constraints. The older agents in the class — exenatide, dulaglutide — are available but generally outperformed. Whatever the medication, the research consistently shows that the men who get the most out of these drugs are the ones pairing pharmacology with genuine lifestyle change. The drug can quiet the noise; what you do with that quiet is still up to you.